BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27967292)

  • 1. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
    Zhang L; McGraw KL; Sallman DA; List AF
    Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
    Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
    Dutta S; Moritz J; Pregartner G; Thallinger GG; Brandstätter I; Lind K; Rezania S; Lyssy F; Reinisch A; Zebisch A; Berghold A; Wölfler A; Sill H
    Ann Hematol; 2022 Apr; 101(4):837-846. PubMed ID: 35083527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.
    Siddon AJ; Weinberg OK
    Clin Lab Med; 2023 Dec; 43(4):607-614. PubMed ID: 37865506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.
    Venugopal S; Loghavi S
    Pathobiology; 2024; 91(1):45-54. PubMed ID: 37839402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Grob T; Al Hinai ASA; Sanders MA; Kavelaars FG; Rijken M; Gradowska PL; Biemond BJ; Breems DA; Maertens J; van Marwijk Kooy M; Pabst T; de Weerdt O; Ossenkoppele GJ; van de Loosdrecht AA; Huls GA; Cornelissen JJ; Beverloo HB; Löwenberg B; Jongen-Lavrencic M; Valk PJM
    Blood; 2022 Apr; 139(15):2347-2354. PubMed ID: 35108372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
    Kojima K
    Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 in AML and MDS: The new (old) kid on the block.
    Marks JA; Wang X; Fenu EM; Bagg A; Lai C
    Blood Rev; 2023 Jul; 60():101055. PubMed ID: 36841672
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Santini V; Stahl M; Sallman DA
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432650. PubMed ID: 38768424
    [No Abstract]   [Full Text] [Related]  

  • 10. TP53 status and impact on AML prognosis within the ELN 2022 risk classification.
    Fleming S; Tsai XC; Morris R; Hou HA; Wei AH
    Blood; 2023 Dec; 142(23):2029-2033. PubMed ID: 37647854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 in MDS and AML: Biological and clinical advances.
    Zhao Y; Chen W; Yu J; Pei S; Zhang Q; Shi J; Huang H; Zhao Y
    Cancer Lett; 2024 Apr; 588():216767. PubMed ID: 38417666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
    DiGennaro J; Sallman DA
    Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
    Pereira MP; Herrity E; Kim DDH
    Ann Hematol; 2024 Apr; 103(4):1049-1067. PubMed ID: 37770618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
    Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih LY; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
    Nat Med; 2020 Oct; 26(10):1549-1556. PubMed ID: 32747829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.
    Chen Y; Zheng J; Weng Y; Wu Z; Luo X; Qiu Y; Lin Y; Hu J; Wu Y
    Ann Hematol; 2024 Apr; 103(4):1211-1220. PubMed ID: 38409598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
    Daver NG; Maiti A; Kadia TM; Vyas P; Majeti R; Wei AH; Garcia-Manero G; Craddock C; Sallman DA; Kantarjian HM
    Cancer Discov; 2022 Nov; 12(11):2516-2529. PubMed ID: 36218325
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Cumbo C; Tota G; Anelli L; Zagaria A; Specchia G; Albano F
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32414002
    [No Abstract]   [Full Text] [Related]  

  • 18. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
    Prokocimer M; Molchadsky A; Rotter V
    Blood; 2017 Aug; 130(6):699-712. PubMed ID: 28607134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic landscape of TP53-mutated myeloid malignancies.
    Abel HJ; Oetjen KA; Miller CA; Ramakrishnan SM; Day RB; Helton NM; Fronick CC; Fulton RS; Heath SE; Tarnawsky SP; Nonavinkere Srivatsan S; Duncavage EJ; Schroeder MC; Payton JE; Spencer DH; Walter MJ; Westervelt P; DiPersio JF; Ley TJ; Link DC
    Blood Adv; 2023 Aug; 7(16):4586-4598. PubMed ID: 37339484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
    Sallman DA; McLemore AF; Aldrich AL; Komrokji RS; McGraw KL; Dhawan A; Geyer S; Hou HA; Eksioglu EA; Sullivan A; Warren S; MacBeth KJ; Meggendorfer M; Haferlach T; Boettcher S; Ebert BL; Al Ali NH; Lancet JE; Cleveland JL; Padron E; List AF
    Blood; 2020 Dec; 136(24):2812-2823. PubMed ID: 32730593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.